Author Archives: Ana de Barros PhD

Invitae Launches Comprehensive Carrier Screening for Genetic Disorders, Including Fragile X

Invitae Corporation has launched the Invitae Carrier Screen, an affordable test designed to inform prospective parents of genetic changes that increase their risk of having a child with an inherited genetic disorder, such as fragile X syndrome. “By providing affordable, comprehensive, high-quality genetic information, Invitae carrier testing can help parents-to-be…

U-Lace, FRAXA Partner to Help Fund Research for Fragile X Syndrome

During Autism Awareness Month in April, the nonprofit FRAXA Research Foundation and shoelace company U-Lace established a new partnership to help fund research for the treatment and cure of fragile X syndrome, the most common inherited cause of autism. The partnership will begin with special marketing programs and the development of custom,…

FDA Decision Clears Way for Phase 2 Clinical Trial of BPN14770

The U.S. Food and Drug Administration (FDA) recently accepted the investigational new drug (IND) application for BPN14770, a small molecule therapeutic agent developed by Tetra Discovery Partners for the treatment of Fragile X syndrome and other autism spectrum disorders. Tetra Discovery now plans to launch a Phase 2 clinical…

Genomics Collaborative Aims to Find New Precision Medicine Methods

Boston-based FDNA has launched a global initiative to promote medical research collaborations and to develop new precision approaches for diagnosing and treating disease, including Angelman syndrome. The initiative, called Genomics Collaborative, uses computer analysis and artificial intelligence technologies to integrate genetic information with the physical and biological characteristics of a particular disease.

Survey